Safety issues for plasma derivatives and benefit from NAT testing.
Manufacturing processes for plasma derivatives are in general highly effective for removal or inactivation of enveloped viruses and the products are safe with regard to the clinically important viruses HIV, HCV and HBV. They are not so effective for the elimination for non-enveloped viruses, especially Parvovirus B19 (B19). A certain risk remains of B19 contamination for some plasma derivatives that is caused, firstly, by the occurrence of highly contaminated donations (up to 10(14)genomes/ml) and secondly, by the extreme heat resistance and small size of B19 which makes it difficult to remove or inactivate. NAT is a beneficial tool for detection of virus contamination. It is routinely used for the detection of HCV-RNA in plasma pools, thereby preventing the processing of HCV-RNA positive material. NAT assays may also be valuable for testing the removal of viruses during manufacturing. This may be especially important if a virus cannot be tested by infectivity assays.
Willkommen
H
H
Department of Virology, Paul-Ehrlich-Institut, Langen, Germany. wilha@pei.de
Schmidt
I
I
Löwer
J
J
D001782:Blood Donors; D016174:Hepacivirus / Q000235:genetics* / Q000302:isolation & purification*; D006801:Humans; D021141:Nucleic Acid Amplification Techniques; D016732:Parvovirus B19, Human / Q000235:genetics / Q000302:isolation & purification; D010949:Plasma / Q000821:virology*; D012367:RNA, Viral / Q000097:blood* / Q000235:genetics*; D015203:Reproducibility of Results; D012307:Risk Factors; D012449:Safety
D012367:RNA, Viral